Lyell Immunopharma/$LYEL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lyell Immunopharma
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Ticker
$LYEL
Sector
Primary listing
Employees
300
Headquarters
Website
LYEL Metrics
BasicAdvanced
$579M
-
-$16.06
-0.15
-
Price and volume
Market cap
$579M
Beta
-0.15
52-week high
$45.00
52-week low
$7.65
Average daily volume
100K
Financial strength
Current ratio
5.281
Quick ratio
5.003
Long term debt to equity
16.89
Total debt to equity
20.545
Profitability
EBITDA (TTM)
-186.746
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-762,355.56%
Operating margin (TTM)
-550,791.67%
Management effectiveness
Return on assets (TTM)
-29.83%
Return on equity (TTM)
-86.98%
Valuation
Price to revenue (TTM)
11,775.878
Price to book
2.12
Price to tangible book (TTM)
2.12
Price to free cash flow (TTM)
-2.811
Free cash flow yield (TTM)
-35.57%
Free cash flow per share (TTM)
-8.823
Growth
Revenue change (TTM)
-40.98%
Earnings per share change (TTM)
-38.80%
3-year revenue growth (CAGR)
-92.48%
3-year earnings per share growth (CAGR)
2.70%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lyell Immunopharma stock?
Lyell Immunopharma (LYEL) has a market cap of $579M as of April 14, 2026.
What is the P/E ratio for Lyell Immunopharma stock?
The price to earnings (P/E) ratio for Lyell Immunopharma (LYEL) stock is 0 as of April 14, 2026.
Does Lyell Immunopharma stock pay dividends?
No, Lyell Immunopharma (LYEL) stock does not pay dividends to its shareholders as of April 14, 2026.
When is the next Lyell Immunopharma dividend payment date?
Lyell Immunopharma (LYEL) stock does not pay dividends to its shareholders.
What is the beta indicator for Lyell Immunopharma?
Lyell Immunopharma (LYEL) has a beta rating of -0.15. This means that it has an inverse relation to market volatility.